Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes.

Clinical and translational science - 1 Jul 2024

Wu Xiaojie, Chen Nanye, Hsu Peiwen, Sun Jing, Li Wenting, Wang Qi, Samira Merali, Wei Qiong, Yu Jicheng, Cao Guoying, Yang Haijing, Wang Lili, Wang Jingjing, Jin Yi, Liu Wei, Wu Jufang, He Jinjie, Lyu Cheng, Zhang Jing

Abstract excerpt

Obstructive hypertrophic cardiomyopathy (oHCM) is a subtype of HCM characterized by left ventricular outflow tract obstruction resulting from cardiac muscle hypertrophy and anatomic alterations in the mitral valve and apparatus. Mavacamten, a cardiac myosin inhibitor metabolized primarily by CYP2C19 in the liver, is the first and only targeted medication approved for the treatment of symptomatic New York Heart...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Benzylamines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to East Asian People

Share to Half-Life

Share to Healthy Volunteers

Share to Uracil

Source

Open in PubMed Open full text

Identifiers

PMID: 39014868
DOI: 10.1111/cts.13877
PMCID: PMC11252221

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes.PMID 39014868Read ↗

French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of MavacamtenSemantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.Semantic proximity Read ↗

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy.Semantic proximity Read ↗

In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitorSemantic proximity Read ↗

The efficacy and safety of pharmacological treatments in patients with hypertrophic cardiomyopathy: a network meta-analysisSemantic proximity Read ↗

Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.Semantic proximity Read ↗

Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites.Semantic proximity Read ↗

Genotype Influences Mavacamten Responsiveness in Obstructive Hypertrophic Cardiomyopathy.Semantic proximity Read ↗

CYP2C19 as a key enzyme in the metabolism of cantharidin in Huh-7 cells and mice.Semantic proximity Read ↗

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.Semantic proximity Read ↗

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.Semantic proximity Read ↗

Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.